在初级穿皮冠状动脉干预前口服尼科兰迪尔对无反流的影响:随机对照试验
Tarek Abdel-Hameed Nagib Ahmed1, Shimaa Sayed Khidr2, Ahmed Abdelnaser Abdelrady2
1Department of Cardiovascular Medicine, Assiut University Heart Hospital, Assiut, 71526, Egypt. tarek.a.n.ahmed@med.aun.edu.eg.
概括
在初级穿皮冠状动脉干预之前口服的尼科兰迪尔显著减少了STEMI患者的无逆流和主要心脏不良事件. 这种治疗改善了心肌再输和左心室功能3个月后.
科学领域:
- 心脏病学
- 药理学
- 干预心脏病学
背景情况:
- 之前的研究表明尼科兰迪尔在ST段升高心肌梗塞 (STEMI) 中通过静脉或冠状动脉产生心脏保护作用.
- 关于口服尼科兰迪尔对STEMI的疗效的数据有限,特别是由于亲肠配方的可用性有限.
研究的目的:
- 评估口服尼科兰迪尔在初级穿皮冠状动脉干预 (PPCI) 之前对无反流的发生率的影响.
- 评估PPCI后在医院和3个月的主要不良心脏事件 (MACE).
主要方法:
- 这是一项随机对照试验,涉及302名接受PPCI的STEMI患者.
- 患者被分配给接受PPCI前口服尼科兰迪尔 (20 mg) 和维持疗法或安慰剂.
- 主要终点是没有回流 (TIMI流量≤2);次要终点包括心肌红色度,ST段分辨率,复极分散和MACE.
主要成果:
- 与对照组相比,尼科兰迪尔组的无反流率显著降低 (11. 9% vs 24. 5%),p=0. 005).
- 尼科兰迪尔的使用是减少无反流的独立预测因子 (OR=0. 43).
- 在3个月的随访期内,尼科兰迪尔组观察到心肌再输的改善,左心室功能和MACE的减少.
结论:
- 在PPCI前口服尼科兰迪尔有效地降低了心肌逆流并增强了STEMI患者的再输血.
- 这种治疗与左心室喷射分数的改善和3个月后MACE的显著减少有关.
更多相关视频
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.6K
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
9.4K
相关概念视频
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
676
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
676
01:28Acute Coronary Syndrome IV: Interprofessional Care
26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
01:26Angina IV: Management
22
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
22
01:16Antianginal Drugs: Nitrates and β-Blockers
751
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
751
01:30Acute Coronary Syndrome III: Diagnostic Studies
23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
01:27Coronary Artery Disease V: Interprofessional Care
30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30